Development of Quantitative Tools for the Characterization and Analysis of the Blood Brain Barrier in Normal and MPS IIIB Mice by Rigney, Sara M.
Dominican Scholar 
Graduate Master's Theses, Capstones, 
and Culminating Projects Student Scholarship 
5-2015 
Development of Quantitative Tools for the Characterization and 
Analysis of the Blood Brain Barrier in Normal and MPS IIIB Mice 
Sara M. Rigney 
Dominican University of California 
https://doi.org/10.33015/dominican.edu/2015.bio.07 
Survey: Let us know how this paper benefits you. 
Recommended Citation 
Rigney, Sara M., "Development of Quantitative Tools for the Characterization and Analysis of 
the Blood Brain Barrier in Normal and MPS IIIB Mice" (2015). Graduate Master's Theses, 
Capstones, and Culminating Projects. 187. 
https://doi.org/10.33015/dominican.edu/2015.bio.07 
This Master's Thesis is brought to you for free and open access by the Student Scholarship at 
Dominican Scholar. It has been accepted for inclusion in Graduate Master's Theses, Capstones, and 
Culminating Projects by an authorized administrator of Dominican Scholar. For more information, 
please contact michael.pujals@dominican.edu. 
 
 
 Development of Quantitative Tools for the Characterization and Analysis of the Blood 
Brain Barrier in Normal and MPS IIIB Mice 
 
 
A thesis submitted to the faculty of  
Dominican University of California  
& BioMarin Pharmaceutical Inc.  
In partial fulfillment of the requirements for the degree  
 
 







































I certify that I have read Development of Quantitative Tools for the Characterization and 
Analysis of the Blood Brain Barrier in Normal and MPS IIIB Mice by Sara Rigney, and I 
approved this thesis to be submitted in partial fulfillment of the requirements for the 
degree: Master of Sciences in Biology at  
Dominican University of California (and the Buck Institute of Aging or BioMarin 




Dr. Anil Bagri MD, PhD 





Dr. Kiowa Bower PhD 
Second Reader   
   
  
__________________________  
Dr. Maggie Louie PhD  







The Blood Brain Barrier (BBB) functions to control homeostasis within the central nervous 
system (CNS) via strict control over the passage of molecules into and out of the brain. The goal of this 
barrier is to protect the CNS from harmful external factors while allowing entry of essential nutrients and 
removal of metabolic byproducts. This restrictive nature of the BBB is due to the protein network at the 
borders of adjoining cerebral endothelial cells known as the tight junctions (TJs) and the relationship of 
other supporting cells and proteins such as astrocytes, pericytes, microglia, and the basement membrane 
and extracellular matrix proteins associated with the endothelial cells. While beneficial in health, the 
restrictive nature of the BBB has proved to be a hindrance towards drug administration in many brain 
diseases, blocking pharmaceutical compounds from diffusing out of the blood vessels and into the brain 
parenchyma. However, certain diseases such as the metabolic disease Mucopolysaccharidosis IIIB, have 
been shown to cause breaches in the BBB’s integrity, thus suggesting a possible mechanism to administer 
treatment around this restriction could be to utilize a specific disease’s own pathology. In order to 
understand the extent of BBB dysfunction a systematic and quantitative analysis of the BBB’s cellular 
and protein components and their relationships in each disease of interest during the disease’s progression 
compared to normal conditions is required. This project used advancing technologies in confocal 
microscopy and 3D image analysis to develop and utilize methodologies to analyze each of the 
components of the BBB in wild type mice with the goal to quantify their relationship with the cerebral 
microvascular endothelial cells. In doing so valuable image processing protocols were developed 
revealing the inadequacies of traditional 2D methods and has helped begin to shed light on the effects of 
MPS IIIB on the BBB including disrupted endothelial cells along the tight junctions, increased astrocyte 
contact area and points of contact with endothelial cells, and no changes in the contact area of desmin 
positive pericytes with endothelial cells. 
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 Role of the Blood Brain Barrier 
The Blood Brain Barrier (BBB) is a physical barricade separating peripheral circulation 
from the central nervous system (CNS)1–4. The primary function of the BBB is to control CNS 
homeostasis through the selective transport of molecules from the vasculature to the brain and 
vice versa.1,2 This selective transport provides the CNS with a specialized protection against 
harmful external factors while still allowing the influx of essential nutrients1,2.   Non-specific 
diffusion across the BBB is restricted to molecules that are lipophilic, contain less than 9 
hydrogen bonds, and are less than 400 Da in size4,5. All other transport across the barrier is 
conducted via specific transporters located on the microvascular capillary endothelial cells5–7.  
This strict control is a product of the configuration of several protein networks and cellular 
components that makeup the BBB1–5,8.  Below the exclusionary components of the BBB will be 
discussed in detail. 
Exclusionary Components of the Blood Brain Barrier:  
Endothelial Cells:  
Endothelial cells make up the inner lining of all blood vessels9. These cells have the 
ability to adapt their structure and formation based on their environment  and as a result, 
endothelial cells in the brain possess unique properties compared to their peripheral 
counterparts9. Microvascular endothelial cells (MVECs) are considered the functional location of 
the BBB due to their lack of pores, that allow quick diffusion through the endothelial cell layer; 
minimal pinocytosis compared to peripheral endothelial cells; increased mitochondrial activity; 
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and the presence of tight junctions lining the intercellular border and limiting paracellular 
diffusion1–3,10.  
Tight Junctions:  
The tight junctions (TJs) are responsible for restricting the diffusion of water soluble 
molecules across the MVECs.1,3,4,11 The TJs are regulated by a complex network of proteins and 
signaling pathways that include but are not limited to: transmembrane proteins such as junction 
adhesion molecule-1 (JAM-1), occludin, and claudins; cytoplasmic proteins including zonula 
occludens 1-3 (ZO1-3); and calcium and phosphorylation pathways1,4,10,12,13. While the TJs of the 
endothelial cells are considered a major component of the BBB, their restrictive nature is not 
intrinsic but rather an induced property caused by interactions with other protein and cellular 
components3,14. These additional elements of the BBB include astrocytes, pericytes, the 
extracellular matrix, and basement membrane, are crucial in maintaining and regulating its 
integrity1,3,11,15.   
Astrocytes:  
Astrocytes are specialized glial cells that tile the CNS in a non-overlapping, organized 
manner16.  In a healthy CNS, astrocytes have roles in development, regulation of blood flow, 
fluid, ion, pH and transmitter homeostasis, synapse function, CNS metabolism, and forma a 
component of the BBB16. When the CNS undergoes trauma, astrocytes respond through a 
process called reactive astroglyosis, a hallmark of CNS structural lesions16. Anatomically, 
astrocytes have a close association with the cerebral MVECs and are located between the 
neurons, pericytes and endothelial cells, communicating with these cells through their foot 
processes1,3,16. Functionally, astrocytes are considered to be critical in the development and 
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maintenance of the BBB; however, the molecular mechanisms and exact roles remain 
unclear17,18. Early studies of astrocytes suggest that their interactions with cerebral MVECs can 
induce barrier properties in these cells during BBB development, however, other studies have 
conflicted with this report1,3,16–20. Additional studies in mice have demonstrated that the ablation 
of reactive astrocytes in mice after CNS trauma prevented BBB repair to occur16. Alternatively, 
increased astrocyte number through reactive gliosis alone is not sufficient to restore BBB 
function19. Astrocytes' signaling properties, via calcium pathways, as well as their ability to 
control blood flow through the secretion of molecular mediators, suggest additional vascular 
regulatory functions1,16–18,20. While most reports vary on the exact role of astrocytes in the BBB, 
the majority conclude that a more detailed investigation into the role and mechanisms of 
astrocytes in the BBB are required for a proper understanding of BBB regulation1–3,16,19–21. 
Furthermore, any characterization of the BBB must take the astrocyte component and in 
particular the glial foot process interaction with endothelial cells into consideration16,17,21,22. 
Pericytes:  
 Pericytes maintain a close association with cerebral MVECs by wrapping around 
microvascular walls with their finger-like projections, stabilizing vessel formation23. Regulatory 
roles of the pericytes include controlling capillary flow, clearance of cell debris, and regulation 
of BBB permeability by aiding in restricting endothelial transcytosis24,25. Additionally, pericytes 
have been shown to regulate BBB-specific gene expression as well as induce polarization of the 
astrocyte endfeet which in turn can induce the barrier like properties in the MVEC.24 In states of 
distress, such as hypoxia, pericytes have been observed to migrate away from the brain’s 




Extracellular Matrix and Basement Membrane:  
The extracellular matrix (EM) and basement membrane function as an anchor for the 
MVECs via interactions of laminin and matrix proteins with integrin receptors2–4. The basement 
membrane, is a 30 to 40 nm thick membrane that separates brain endothelial cells from pericytes 
and astrocytes by ensheathing the capillaries while still bordering the astrocyte foot processes3. 
Protein components of both the EM and basement membrane include collagen, elastin, 
fibronectin, and laminin, as well as proteoglycans, heparan sulfate, chondroitin sulfate and 
keratan sulfate.  Disruption of the extracellular matrix and/or basement membrane is associated 
with increased BBB permeability2–4. 
Microglia: 
Microglia are the resident macrophages of the CNS and have been reported by some to 
potentially play a role in modulating the BBB1,4,11. The role of microglia as structural component 
of the BBB is controversial, however, their ability to regulate vascular permeability via secretion 
of cytokines suggests that they may have a role in regulating BBB integrity, particularly in the 
context of states of inflammation1,4.     
Challenges of Drug Delivery into the CNS: 
The blood brain barrier becomes a hindrance toward drug administration in disorders of 
the CNS11. The restriction of large and/or hydrophilic molecules from crossing the BBB cause 
many therapeutic pharmlogical compounds to be excluded from entry into the CNS by the BBB. 
Most effective treatment methods therefore must often rely on invasive methods, such as 
intracerebroventricular (ICV) infusions, that bypass the BBB through direct delivery into the 
CNS7.  Studies researching the structure and function of the BBB have allowed progress to be 
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made on finding less invasive methods to target drug delivery to the brain. Strategies that have 
evolved from these BBB studies include controlling transport receptors to modulate influx of 
specific drug compounds as well as a more comprehensive approach of increasing BBB 
permeability2,5,6,26,27.   
BBB and Disease 
Certain disorders that affect the CNS can cause alterations to the BBB’s structure and 
integrity. The impact of neurodegenerative diseases such as Alzheimer's and Parkinson's 
diseases' on the BBB have been some of the most extensively studied4,28. Other diseases studied 
include: multiple sclerosis, infectious diseases like meningitis and HIV, epilepsy, stroke, brain 
tumors and some metabolic diseases1–3.  In most cases, disease progression is associated with the 
loss of the BBB's strict transportation control due, in large part, to the disruption of one or more 
of the cellular components noted above1–4,21,29,30  
Understanding BBB Breakdown in Metabolic Diseases:  
Little is known about the state of the BBB in most genetic metabolic diseases including 
the lysosomal storage disorder family, Mucopolysaccharidosis (MPS)11,27,31.  One member of 
interest in the MPS family, MPS IIIB also known as Sanfilippo Syndrome, is caused by a 
deficiency of the enzyme N-acetylglucosaminidase (Naglu)32. The lack of Naglu results in the 
accumulation of heparan sulfate in the lysosomes, causing cerebral and multi-organ 
abnormalities and ultimately death around the ages of 11-20 years31. Currently there is no 
approved treatment for MPS IIIB however, a common treatment for similar MPS disorders is 
enzyme replacement therapy (ERT). In order for ERT to be an effective treatment for MPS IIIB 
it has been hypothesized that the excess heparan sulfate must be cleared from the brain, 
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therefore, any potential treatment must be able to cross the BBB27. Since heparan sulfate 
accumulation occurs in multiple cell types it is reasonable to hypothesize that there will be 
changes to BBB structure and function in MPS IIIB. While a few studies to understand the 
effects this disease has on BBB integrity were done in both humans and in naglu knockout 
mouse models of MPS IIIB the exact nature of these changes remains unclear31,33–35.  Reported 
physical changes to the brain in MPS IIIB human patients include cortical atrophy, ventricular 
enlargement, callosol atrophy, cerebellar changes and purkinje cell abnormalities35. One study 
examined some of the structural impairments of the BBB in MPS IIIB mice and reported leakage 
of Evans Blue and Albumin, mostly in the cerebellar lobules, cerebral cortex, hippocampus and 
the midbrain suggesting that MPS IIIB does result in disruption of the BBB but the basis of this 
disruption is presently unknown31. Other findings included degenerating astrocytes, increased 
number of vascular macrophages, and capillary endothelia abnormalities that increase with age. 
However, these reports are limited in their analysis and no extensive quantified model of the 
BBB in MPS IIIB exists yet31,35.   
Implications of BBB Disruption:  
  While the mechanisms may differ amongst disease states, the overall effect of disease on 
the BBB is altered permeability due to the reorganization and/or loss of TJ proteins, as well as 
changes in the BBB's supporting cells2–4. Although these alterations in permeability can 
contribute to the physical manifestations of diseases, it also creates the possibility of utilizing 
these naturally occurring BBB breaches as a pathway for drug administration into the brain11. In 
order to understand the extent of BBB dysfunction and its potential for transport of 
pharmacologic substances into the brain, a detailed quantitative analysis of the BBB in specific 




Development of Tools to Study the BBB 
Protein and cellular components of the BBB can be analyzed in biochemical assays by 
measuring fluctuations in protein concentrations as well as activity, however, these studies 
provide no information about the distribution of these components or about their morphological 
details,  such as how many astrocyte foot processes are in contact with a specific blood vessel. In 
vitro models of the BBB have been developed but they cannot perfectly simulate the in vivo 
environment and therefore provide limited information36,37. Immunohistochemistry, however, 
specifically immunofluorescence, offers the ability to visualize and study the localization and 
morphological details of multiple proteins and cells of interest in vivo38. Therefore, this 
technique has the ability to be a powerful tool in characterizing the interactions of the BBB 
components.  
Additionally, advances in microscope and image processing technologies offer new 
options to increase the capacity of visualization and analysis that were not possible before.  
Epifluorescence microscopy is the standard form of imaging for most immunofluorescence 
image analysis39,40.  In this method, a light source such as a mercury arc lamp is used to excite 
the fluorophores in the tissue sample. The desired excitation wavelength is set as light from the 
lamp source passes through an excitation filter placed between the light source and the tissue 
sample. The excitation light is directed toward the tissue sample by a dichroic mirror.  Light that 
is emitted from the sample’s excited fluorophores is then directed upward toward the objective 
lens and detector.  The emitted light passes back through the dichroic mirror and a barrier filter 
which blocks the shorter wavelengths of the excitation light from reaching the detector39–41.  The 
result of this method of microscopy is a 2D image of a single focal plane containing signal only 
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from the fluorophores excited in the tissue sample. Limitations to this imaging method, however, 
exist that could make analyzing the BBB interactions of interest in detail difficult.  One 
limitation to epifluorescence microscopy is that the tissue sample is completely illuminated by 
the excitation light42.  While most of the light is redirected to the focal point of the detector out 
of focus light from the surrounding excited tissue area still reaches the detector and creates a 
haze across the image.  In higher objectives and with thicker tissues the amount of out of focus 
light increases making it difficult to obtain a focused image39,40,43. Additionally, epifluorescence 
microscopes cannot focus through multiple planes limiting the field of view of the images 
acquired to a single focus plane as well as increasing the amount of out of focus light in the 
image39,43,44.  
Confocal microscopy offers a solution to the shortcomings of the epifluorescence 
microscopy by simply blocking the out of focus light from reaching the detector39,43,45.  The 
excitation light source in confocal microscopy is often from a focused laser beam rather than a 
lamp source limit the surface area of tissue sample that is excited at any specific time. 
Additionally, a pinhole placed in the emitted light’s pathway effectively blocks out of focus light 
from reaching the detector 39,43. As a result of this pinhole a further advantage of confocal 
microscopy is the ability to acquire serial optical sections composed into high resolution image 
stacks (z-stacks,) which greatly improve the vertical resolution of the image39,43,44. These z-
stacks can be used to create maximum projections images which provide a better resolved 2D 
image than can be produced using an epifluorescence. Additionally, these confocal z-stacks can 




Traditional image processing of histological microscopic images has occurred in 2D 
utilizing software such as the open access program ImageJ. However, any BBB characterization 
would require a detailed blood vessel analysis and characterization.  An accurate characterization 
of the blood vessels is necessary as the BBB function, and thus the cellular components 
interactions, is reported to vary in the different types of microvasculature45,48,46. Therefore, 
before any assertions can be made about how components of the BBB interact with MVECs it is 
necessary to be able to distinguish between capillaries, venules, and arterioles48,46.  Typically, 
histological characterization of blood vessels is performed by measuring the diameter of the 
blood vessels apparent cross sections in 2D. However, due to the tortuosity of blood vessels and 
the limited field of view of 2D images traditional methods of measuring 2D vessel diameters can 
lead to inaccurate characterization of vessels by measuring regions that are too long, short or not 
the true diameter46,49. (Fig.1).  This limitation of 2D measurement is hypothesized to be a factor 
in the variability of characterization parameters of the BBB which are proposed to be highly 
sensitive to vessel diameter46.  The development and improvement of 3D software offers a 
possible solution to the short comings of 2D analysis and should be a valuable asset in 
developing both WT and MPS IIIB BBB models47,50.  The BBB with its many interacting 
components offers a great model system to explore the advantages of 3D analysis over 2D.  
In order to have an in depth understanding of the changes that occur in the BBB during 
disease the structural components of the BBB must be able to be characterized in a reliable and 
reproducible manner. This study aims to utilize the specificity of immunohistochemistry assays 
and advancements in 3D image processing to develop a unique quantitative structural model of 
the protein and cellular components of the BBB in both wild type and MPS III mouse models. 
The overall goal in creating this model is to find a reliable and reproducible method of 
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characterizing the BBB in both normal and diseased animals in order to provide useful 







Materials and Methods:  
Tissue Preparation 
Tissues were perfusion fixed with formalin to preserve vascular structure and then 
cryoprotected with 30% sucrose solution to reduce artifacts that are commonly introduced during 
tissue freezing. Frozen tissues were sectioned on a cryostat into 50 µm thick sections. For short 
term storage tissues were stored in 1X PBS solution with 0.01% NaN3 at 4°C. For long term 
storage tissues were stored at -20°C in a cryoprotectant buffer of 30% sucrose (w/v), 1% 
polyvinyl-pyrrolidone (w/v), 50 % 0.1M phosphate buffer (v/v), and 30% ethylene glycol (v/v).  
IHC Protocol 
Antibody Selection: 
Figure 1: The Importance of 3D Analysis in Blood Vessel Characterization in BBB Analysis 
A) The 2D measurement of what appears to be a blood vessels cross section B) 3D rendering of the same blood 
vessel and line measurement shows the line drawn is not across the diameter but rather at a diagonal from one end 
of the blood vessel to the other. 3D measurement may provide a more accurate method of measuring and 





Antibodies to detect astrocytes, pericytes, microglia, tight junctions, and the basement 
membrane/extracellular matrix were tested and optimized through a series of IHC experiments.  A 
description of the target antigens to label each BBB component can be seen in Table 1 and the full 
list of tested antibodies can be viewed in Table 2.  A secondary antibody for mouse IgG was also 
used alone to detect endogenous IgG in order to measure vascular leakage across the BBB. 
 
Table 1: Target Antigens for Labeling Blood Brain Barrier Components 
BBB Component Antigen Description 
Endothelial Cells CD31 
 Also known as Platelet Endothelial Cell Adhesion Molecule 
(PECAM-1). 
 Integral membrane glycoprotein expressed on platelets, monocytes, 




 Zonula occluden 1 
 Peripheral membrane protein of the tight junctions 
 Expressed on the cytoplasmic surface of endothelial cells 
Occludin 
 Integral plasma membrane tight junction protein 
 Main component of the tight junctions 
E-Cadherin 
 Endothelial cell specific adhesion molecule  
 Located at junctions between endothelial cells 
Claudin-1 
Claudin-5 




 Glial Fibrillary Acid Protein 
 Class III intermediate filament protein expressed in astrocytes 
 Distinguishes astrocytes from other glial cells during development 
Pericytes 
PDGFRB 
 Tyrosine-kinase receptor 
 Expressed by pericytes, fibroblasts and astrocytes 
ASMA 
 Alpha Smooth Muscle Actin 
 Expressed in the internal structure of smooth muscle cells and 
pericytes 
NG2 
 Neuronglial 2 
 Membrane chondroitin sulfate protein 
 Expressed on surface of pericytes, glial precursor cells, 
chondroblasts and proliferating capillary endothelial cells 
Desmin 
 Muscle specific class III Intermediate Filament protein 
 Expressed on most muscle types and pericytes 
Basement 
Membrane 
Collagen IV  Major structural component of basement membranes 
Microglia IBA1 
 Ionizing Calcium-Binding Adaptor Molecule 1 
 Specifically expressed in macrophages and microglia 
 Up regulated expression during microglia activation 
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Phase 1 Development: IHC Protocol Development Antibody Optimization 
Sections were stained while floating in 6 and 12 well plates rather than mounted on a 
slide in order to improve antibody penetration and staining quality. An immunohistochemistry 
staining protocol was developed to accommodate these thick floating tissue sections. In a twelve 
well plate, sections were first washed in PBS plus 0.3% Triton-X (PBT) for 15 minutes followed 
by incubation in 10% blocking serum (animal host of the secondary antibody) for one hour. After 
blocking sections were incubated in primary antibody diluted in 2% normal serum overnight at 
4˚C. Primary antibody concentrations varied based on the antibody and were determined for each 
candidate through a series of optimization experiments to determine the dilution that produced 
the best signal to noise ratio before they could be used in this analysis. Controls for each IHC 
experiment were placed in a well containing incubation buffer without antibody. Following 
primary incubations tissues were washed as follows: 3 x 20 min; 3x 1 hour for a total of four 
hours in 6 well plates.  Tissue samples were then transferred to 12 well plates and incubated in 
secondary antibody diluted in 2% normal serum for one hour at room temperature.  Secondary 
antibody concentrations were optimized for each primary.  Following secondary antibody 
incubations samples were washed in PBT following the same four hour wash that occurred after 
primary incubation. The sections were then counterstained with DAPI (0.1 µg/mL, 5 min), 








Phase 2:  IHC for BBB Characterization 
Using the IHC protocol and tested antibodies from phase one both WT and MPS IIIB 
brain tissue sections from -1.28 to -2.75 mm of bregma were stained in the combinations listed in 
Table 3.  
    
Table 2: BBB Components Tested Antibodies 










CD31 RD Systems/AF3628 Goat 0.2 mg/mL 
CD31 Abcam/ab28364 Rabbit Not Specified 
CD31 Sigma/SAB4502167 Rabbit 1mg/mL 
CD31 Millipore/CBL1337 Rat 0.5 mg/mL 
CD31 Abcam/ab56299 Rat 0.5 mg/mL 




GFAP Sigma/SAB2500462 Goat 0.5mg/mL 
GFAP Sigma/ G3893 Mouse Not Specified 









Desmin Novus/NB120-15200 Rabbit 0.2 mg/mL 
PDGFRB Novus/NBP1-43349 Rat 0.5 mg/mL 
ASMA Novus/NB110-55432 Rabbit  Not Specified 
PDGRB Cell Signaling/3169 Rabbit Not Specified 
NG2 Millipore/MAB5384 Mouse 1 mg/mL 
NG2 Millipore/AB5320 Rabbit 1 mg/mL 
ASMA Abcam/ab7817 Mouse 0.2 mg/mL 
ASMA Abcam/ab5694 Rabbit  0.2 mg/mL 





Millipore/AB769 Goat 0.4 mg/mL 
Collagen 
IV 









ZO-1 Invitrogen/33-9100 Mouse 0.5 mg/mL 
ZO-1 Invitrogen/61-7300 Rabbit 0.25 mg/mL 
Occludin Invitrogen/33-1500 Mouse 0.5 mg/mL 
Occludin Invitrogen/71-1500 Rabbit 0.25 mg/mL 
E-Cadherin Invitrogen/33-4000 Mouse 0.5 mg/mL 
Claudin-1 Invitrogen/51-9000 Rabbit 0.25 mg/mL 
Claudin-1 Invitrogen/37-4900 Mouse 0.5 mg/mL 
Claudin-5 Invitrogen/35-2500 Mouse 0.5 mg/mL 
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Donkey anti Goat Alexa Fluor 555 
(Life Technologies) 
Donkey anti Rat Alexa Fluor 647 
(Abcam Inc.) 
Donkey anti Rabbit Alexa Fluor 488 
(Life Technologies) 












Donkey anti Rabbit Alexa Fluor 555 
(Life Technologies) 
Donkey anti Goat Alexa Fluor 488 
(Life Technologies) 











Donkey anti Rabbit Alexa Fluor 555 
(Life Technologies) 
Donkey anti Goat Alexa Fluor 488 
(Life Technologies) 










Donkey anti Goat Alexa Fluor 555 
(Life Technologies) 
N/A 





Image Acquisition:  
Phase One: Imaging for Antibody Optimization 
Initial image analysis of the antibody testing experiments used a Leica DM 4000 series 
fluorescence microscope at 20x and 40x oil objectives.  
Phase Two: Imaging for BBB Characterization:  
Due to the use of thick tissue sections and the limitations described earlier of the 
epifluorescence microscope, particularly out of focus light effecting the image quality and the 
inability to image more than one focal plane, a confocal microscope was required to produce 
image stacks (z-stacks) at both a high objective and resolution.  Images used in quantification 
protocol development and BBB characterization were acquired using a Leica TCS SP8 confocal 
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microscope. Images were acquired at a 40x objective with the number of z-stack slices varying in 
order to capture the maximized depth in the z-axis. Image files acquired from the Leica TCS SP8 
confocal microscope were saved and exported as lif files.  
Image Quantification:  
Blood Vessel Isolation: 
 Using the commercially available Volocity, a 3D image visualization and quantification 
software program by Perkin Elmer, 3D representations were constructed from the blood vessel z-
stacks acquired from confocal microscopy (Fig. 2A). The confocal lif image stack files were 
imported into Volocity. Blood vessels of interest were isolated using a measurement protocol 
developed in Volocity’s quantification program. Blood vessel populations were created through a 
threshold detected and filtered by volume size (μm3) starting at 5000 μm3 and adjusted until just 
the vessel of interest was selected. A region of interest (ROI) was then created of the selected 
blood vessel of interest (Fig. 2B). The image was then cropped to the selection and a new 3D 
image was automatically generated containing just the vessel of interest (Fig. 2C).  
Realigning Isolated Blood Vessels: 
Isolated blood vessels were resliced to align the vessel cross section along the xy axis. An ROI of 
the blood vessel was again created by a threshold detection. When the vessel image with the ROI 
is viewed in Volocity’s 3D slice mode a 3D isosurface representation of the blood vessels was 
created from the ROI (Fig. 2D). The 3D vessel representation was then rotated around its axis 
until the vessel cross section was aligned along the image’s xy plane (Fig. 2E). The image was 




Area Measurement of Blood Vessel Cross Sections: 
The resliced blood vessel image stacks were exported from Volocity as ics/ids files in 
order to be imported into ImageJ. In ImageJ the ics/ids vessel image stack files were split into 
individual channel image stacks. The CD31channel, representing endothelial cells, image stacks 
were saved as tiff files. These CD31 tiff images were batch processed to measure the interior 
area of the blood vessel cross section of each slice in the image stack using a custom 
measurement macro (Fig. 2).  The results table generated were saved and exported into Microsoft 
Figure 2: Isolation and Realignment of Blood Vessels in 3D Using 3D reconstructions of the blood vessel image stacks (A), 
taken with a confocal microscope, the blood vessels can be threshold detected to create an isosurface region of interest (B); 
isolated from the rest of the image (C) and realigned so that their cross sections and therefore their diameters align with the 




Excel where data for each vessel image were sorted by file name.  The diameters for each 
measured slice were calculated from the area. All slice diameters were averaged to determine the 
average cross section diameter for each blood vessel. As a control, a 3D cylinder volume was 
created from a stack of 2D circles drawn with a known diameter and micron/pixel scale. This 
control image stack was imported into Volocity where the 3D volume was constructed and 
underwent the same detection, isolating, and reslicing as the blood vessel volumes. The control 
volume image stack was then exported from Volocity as an ics/ids file and imported into ImageJ 
where it underwent the same cross sectional area measurements as each of the blood vessel 
image stacks.  
Figure 3:  ImageJ Custom Cross Sectional Area Measurement Protocol: For each slice in a stack the threshold 
detection was set to 1-255. A binary representation of each image slice was created and inverted. An open command 
was run to fill any minor gaps in vessel walls. Measurements run were for object area. Size limitations of 25-500 µm2 
was set to eliminate noise detection.  Outline images of what was measured in each slice were created. Results were 




Classification of Blood Vessels by Diameter Size:  
 The average cross section diameters were used to classify each of the measured blood 
vessels into three categories: capillaries: < 10 μm, pre and post capillary arterioles and venules: 
11-20 μm, and arterioles and venules: > 20 μm. Image files of vessels in the capillary and pre 
and post capillary vessel groups were used in further quantitative analysis for BBB 
characterization.  Vessels in these two groups represent the largest components of the vascular 
surface area within the brain and the vessels where BBB is most critical. 
Astrocyte and Pericyte Surface Area Coverage of Blood Vessels:  
Blood vessel, astrocyte and pericyte populations were created through threshold detection 
of each respected channel.  Two new populations called Astrocyte Intersection and Pericyte 
Intersection were created to detect where voxels (3D pixels) from each astrocyte or pericyte 
channel coexisted with the blood vessel channel by using the “intersect” command in Volocity. 
(Fig. 4). Surface area measurements (μm) of the astrocyte intersection and pericyte intersection 
populations were performed simultaneously. The measurement results were exported into 









Figure 4: Example of Using 3D Analysis to Measure 
Pericyte Coverage of Blood Vessels 
A-B: 3D rendering of CD31 staining blood vessel 
endothelial cells (yellow) costained with Desmin 
(pink) in the process of measuring pericyte coverage. 
A pericyte being measured (brown) can be seen from 
two different angles.  
C-D: Pericyte coverage is measured based on where 
voxels from the desmin channel coexist (intersect) 
with voxels from the endothelial cell channel. This 
intersection point is shown in white 
E): A close up view of a portion of a pericyte of 
interest (brown) and the intersection point with the 
blood vessel to be measured (white) shows how a 
portion of the pericyte is embedded in the wall of the 
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Astrocyte Points of Contact Measurement: 
In addition to measuring surface area of CD31 and GFAP intersection in Volocity, the 
amount of these contact points made was counted and totaled for each blood vessel 
simultaneously with the surface area measurements.  
Pericyte Volume Measurement: 
 Total pericyte volume was measured in Volocity concurrently with the surface area 
analysis. The volume of the pericyte population detected from the desmin channel was measured 
to analyze the volume of the entire pericyte rather than just where the pericyte intersected with 
the blood vessel.  
Endothelial Cell Disruption Measurement: 
 To measure the extent of any disruption of the endothelial cells and/or their tight 
junctions the ratio of the intact endothelial cells surface area to that of the whole blood vessels 
surface area was calculated.  Surface area of the CD31 channel was measured from the entire 
blood vessel image. ROIs were drawn around areas where the distinct cobblestone pattern, 
marking the MVEC outlines were visible. The surface area of CD31 within these ROIs was 
measured. Ratios of the total intact endothelial cell surface area to that of the total blood vessel 
CD31 surface area were calculated from these measurements.  
Calculations and Statistical Analysis 
 All additional data calculations and analysis were performed using Microsoft Excel and 





IHC Assay Development: 
Approximately 30 different antibodies have been tested for both their sensitivity and 
specificity at detecting each component of interest in the BBB. Antibodies for the identification 
of astrocytes, pericytes, microglia and the basement membrane/extracellular matrix have been 
identified and fully optimized through a series IHC experiments to determine their ideal working 
concentration. All tested TJ protein specific antibodies however failed to produce positive 
results.  Below is a detailed description of the IHC assay results and Table 4 presents a summary 






Table 4: Working Antibodies 








CD31 RD Systems/AF3628 Goat 1:50 
CD31 Abcam/ab28364 Rabbit 1:50 
IB4 Life Technologies/I21411 N/A 1:100 
Astrocytes 
  
GFAP Sigma/SAB2500462 Goat 1:1000 
GFAP Sigma/ G3893 Mouse 1:1000 




Desmin Novus/NB120-1520 Rabbit 1:100 
ɑSMA Abcam/ab7817 Mouse 1:100 
ɑSMA Abcam/ab5694 Rabbit 1:100 




Collagen IV Millipore/AB769 Goat 1:50 




Endothelial Cell Markers:  
Antibodies were evaluated 
for both their sensitivity and their 
specificity to determine their 
overall effectiveness.  Of the six 
reagents (5 antibodies and one 
probe) tested as markers for 
endothelial cells, three produced a 
positive signal. These three 
reagents include two antibodies, 
Goat anti-CD31 (RD 
Systems/AF3628) and Rabbit 
anti-CD31 (Abcam/ab28364), and 
the probe Isolectin B4- Alexa 
488 (IB4). With all three 
reagents the staining pattern 
matching the branching of blood 
vessels of various sizes could be 
identified homogenously across 
the brain sections. Specificity refers to whether or not an antibody detects only its target antigen. 
Optimization experiments, using the antibodies at various concentration levels were performed to 
test each antibodies specificity and to find their ideal signal to noise ratio. In these experiments, 





Figure 5:  Immunohistochemical Assay Development of Endothelial Cell l 
Markers A) Goat anti CD31 (RD Systems/AF3628) optimized at a concentration 
of 1:100 produces a strong signal to noise ratio with the correct blood vessel 
staining pattern. An example of ideal antibody sensitivity and specificity.  B) 
Rabbit anti CD31 optimized at 1:50 also produces a good signal to noise ratio 
and correct staining pattern. C)  Isolectin B4-AlexaFluor 555 optimized at 1:100 
stains blood vessels and microglia (arrow) thus demonstrating a lack of 
specificity required for image analysis. D-E: In order Rabbit anti CD31 
(Sigma/SAB4502167), Rat anti CD31 (Millipore/CBL1337), and Rat and CD31 
(Abcam/ab56299). All three images have no positive signal and demonstrate 
the results of antibodies with poor sensitivity.  All images are taken at a 10x 




ranging from 1:10 to 1:1000 also produced a high background signal that could not be avoided 
without increased wash times. As a result the general IHC protocol described above was adapted 
to increase wash number and duration after antibody incubations from 1 hour to 4 hours with 
multiple changes of buffer. These optimization experiments found that the working concentration 
ratio for the Goat anti-CD31 antibody was 1:500 and the Rabbit anti-CD31 was 1:50 (Fig. 5). 
Isolectin B4 (IB4), a lectin that has been used to label endothelial cells in tissue was found to 
indeed statin blood vessels but also produced a strong signal in microglia, as has been previously 
described, thus lacked the specificity needed for adequate image analysis and was eliminated as a 
blood vessel marker.  All other blood vessel markers tested did not produce a positive signal at 
the sensitivity testing stage (Fig. 5).  
Astrocyte Markers 
Three antibodies were tested and 
successfully optimized as astrocyte markers. 
These antibodies were Goat anti-GFAP 
(Sigma/SAB2500462), Mouse anti-GFAP 
(Sigma/ G3893) and Rat anti-GFAP 
(Invitrogen/13-0300). All three antibodies 
were tested for sensitivity and specificity 
similar to the endothelial cell markers and all 
three produced a satisfactory signal to noise 
ratio at concentration ratios of 1:1000. 
During image analysis, positive staining of 
astrocytes was confirmed by visualization 
A B 
C D 
Figure 6:  Immunohistochemical Assay Development of Astrocyte 
Markers. A) Goat anti GFAP (Sigma/SAB2500462).  B) Rat anti GFAP 
(Invitrogen/13-0300). C)  Mouse anti GFAP (Sigma/ G3893). D) Image 
provided by Abcam as an example of a positive GFAP signal. All three 
antibodies (A-C) produce a staining pattern consistent with that in D and 
can therefore be confirmed to produce a positive signal. The antibodies 
in A-C have all been optimized to work at 1:1000 with minimal 






of the star shaped morphology of the astrocyte body with its many foot process as well as the 
organized non-overlapping orientation of the astrocytes (Fig. 6).  Additionally, when all GFAP 
antibodies were costained with an endothelial cell marker, the end feet of the astrocytes were 















Figure 7: GFAP Costained with CD31 Illustrates Astrocyte 
Interactions with Blood Vessels 
When costained with CD31 (red), GFAP (green) can be seen 
to positively stain astrocytes as they interact with blood 
vessels. Image was acquired using a confocal microscope in 
order to capture the detail of the astrocyte foot processes 





Out of the eight different 
pericyte markers that were tested 
and only three were determined to 
provide appropriate staining 
patterns: rabbit anti-desmin 
(Novus/NB120-15200), mouse 
anti-alpha smooth muscle actin 
(ASMA) (Abcam/ab7817), and 
rabbit anti-ASMA 
(Abcam/ab5694).  All other antibodies listed in Table 1 did not produce the appropriate staining 
pattern and were not pursued further. When tested for specificity all three antibodies produced a 
high signal to noise ratio and the working concentrations were determined to be 1:100 for all 
three (Fig. 8).  A positive pericyte signal was further confirmed for each of the working 
antibodies by a costain with a CD31 antibody. 
The pericyte staining was morphologically 
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Figure 8:  IHC Assay Development of Working Pericyte Markers 
A) Rabbit anti Desmin (Novus/NB120-1520), B) Rabbit anti Alpha Smooth Muscle Actin 
(Abcam/ab5694), and C) Rabbit anti Alpha Smooth Muscle Actin represent the three 
potential pericyte markers that produced a positive signal. The other five antibodies 
(not pictured) failed to produce a signal. Even without a blood vessel costain the 
staining pattern can be seen to correspond with the location of blood vessels giving 
support that these antibodies are detecting pericytes. Desmin (A) appears to produce 
signal in smaller vessels as well as larger where as smooth muscle actin (B-C) appears 
limited to larger vessels. Scale Bar = 20 μm. 
Figure 9: Confocal Image of a Desmin and CD31 Antibody 
Costain Confirms Pericyte Marker 
Desmin (green) is confirmed in this costain with CD31 (red) 
to be functioning as a pericyte marker based off both its 
association with endothelial cells and the morphology of the 





One antibody was tested as a microglia marker, Goat anti Iba1 (Abcam/AB5076). This 
antibody proved to be sensitive and specific at detecting microglia at a working concentration 
ratio of 1:1000. The microglia were detected by their unique ramified shape, most common 






Tight Junction Markers 
Several tight junction markers were tested and retested however none have been 
determined to detect tight junction proteins at this point.  However, CD31 also known as platelet 
endothelial cell adhesion molecule (PECAM) has been reported to be expressed in the TJs of 
endothelial cells10,51. This cobblestone TJ staining pattern was observed with both CD31 
(PECAM) antibodies when used at their optimal concentrations (Fig. 11). 
 
Figure 10: IHC Assay Development of IBA1 as a Microglia Marker 
A)  Goat anti IBA1 (Abcam/AB5076) optimized at 1:1000 compared to the image provided by the 
supplier Abcam of the expected staining results of this antibody. This antibody matches the staining 
pattern of the expected results as well as the known staining pattern of microglia in the CNS including 










Basement Membrane Markers 
Two antibodies have been tested as a basement membrane marker: Goat anti-Collagen IV 
(Millipore/AB769) and Rabbit anti-Collagen IV (Abcam/ab19808).  Visually at first, the 
basement membrane staining pattern looks similar to that of the blood vessel markers, however, 
the basement membrane ensheathes the endothelial cells and therefore can be seen as the outer 
layer when costained with an endothelial cell marker.  Of the two antibodies tested, the Goat 
anti-Collagen IV produced the most sensitive and specific staining pattern of the two with a 
working concentration ratio for 1:50. The rabbit anti-collagen IV antibody still produced good 
sensitivity and specificity at 1:500. 
Blood Vessel Classification by Average Diameter Calculation: 
Blood vessels were grouped into categories based on their calculated average diameter 
from the measured cross section area of each slice in the blood vessel image z-stack. Before the 
Figure 11: Anti CD31 Antibodies Functions as a Tight Junction Marker A-B represent confocal images of two different 
blood vessels stained with CD31 (green). Positive CD31 signal can be seen brightest as outlines (junctions) of 
endothelial cells that line blood vessels. CD31 has been reported to be localized in the tight junctions of the 
endothelial cells these images give evidence to support these reports and suggest that CD31 will work as a marker for 




blood vessels could be categorized however, the measurement results were quality checked to 
confirm that the areas measured matched the imaged blood vessel cross section and that a 
minimum of 10 slices in each z-stack were measured. If a blood vessel image did not meet both 
minimum requirements the image was classified as failing the QC process and not included in 
further analysis.   
Blood vessels that passed the QC process were categorized based on their average 







Tables 6 and 7 provide the numerical classification of blood vessels in each size group 
for the cortex and thalamus of the WT and MPS IIIB mice respectively. While vessels were 
categorized into four different groups only vessels that fell into groups one and two were used in 




TABLE 5: MICROVESSEL CLASSIFICATION BY DIAMETER SIZE 
< 10 µm Capillary 
11-20 µm Pre-Capillary  Arterioles 
Post-Capillary Venules 








Table 6: Cortex Blood Vessel Categorization 
Genotype Animal Name 
Capillaries 
< 10  µm 







> 20 µm 
WT 
WT-1 Cortex 20 14 1 
WT-2 Cortex 21 9 2 
WT-3 Cortex 30 5 0 
WT-4 Cortex 17 7 1 
WT-5 Cortex 8 4 0 
MPS 
IIIB 
MPS IIIB-1 Cortex  17 8 0 
MPS IIIB-2 Cortex 18 5 0 
MPS IIIB-3 Cortex  11 10 0 
 MPS IIIB-4 Cortex 21 6 0 
 MPS IIIB-5 Cortex 23 6 0 
 
Table 7: Thalamus Blood Vessel Categorization 
Genotype Animal Name 
Group 1: 
Diameter 




Group 4: Diameter > 
20 µm 
WT 
WT-1 Thalamus 15 17 4 
WT-2 Thalamus  24 7 2 
WT-3 Thalamus 21 13 0 
WT-4 Thalamus 12 13 4 





15 19 5 
MPS IIIB-2 
Thalamus 
19 13 3 
MPS IIIB-3 
Thalamus 
16 12 2 
 MPS IIIB-4 
Thalamus 
21 15 0 
 MPS IIIB-5 
Thalamus 
20 16 2 
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Correlation of 2D Vessel Area Measurement Vs 3D Vessel Area Measurement Confirms 
Improved Accuracy of 3D Analysis 
 Initial image analysis provided first hand evidence to support literature claims that 2D 
blood vessel diameter measurements results in inaccurate data (Fig. 1). As a result of these early 
findings and literature reports, extensive work was done to develop the protocol used in this 
project with the goal accurately measure blood vessel cross sectional areas in 3D.  In addition to 
the control stacks measured, confirmation that 3D analysis of blood vessel cross sectional areas 
is advantageous over 2D analysis was assessed by taking a single slice representing the apparent 
cross sections from 32 blood vessel image stacks at random to undergo analysis using traditional 
2D methods. Each chosen image slice was analyzed by manually making a line measurement 
across each vessel’s apparent diameter and calculating the area from it. The results of this 
measurement were then graphed versus the 3D measured areas of the same vessels.  The results 
of this comparison gave an r 2 value of 0.008616 showing very little correlation between the two 
measurement methods (Fig. 12). Additionally when maximum projections* of the blood vessel 
image stacks were composed they showed the apparent vessel diameters measured were not 
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Figure 12: No Correlation Between 2D and 3D 
Blood Vessel Area Measurement Protocols: 
Results of blood vessel cross sectional area 
were measured using both traditional 2D line 
measurements and 3D analysis to help confirm 
the inaccuracies of 2D analysis. When the 
results of the two analysis methods were 
plotted against each other no correlation was 
observed to help confirm the necessity of 3D 
analysis 
 
Figure 13: Traditional 2D Blood Vessel Measurement Results in Inaccurate  Characterizations Apparent 
cross section line measurement in a 2D image slice (A) compared to the maximum projection of the entire 
blood vessel image stacks(B) highlights the inaccuracies of 2D vessel characterization and provides support 





Changes in Astrocyte Foot Process Coverage of MVECs:  
The changes in astrocyte foot process contact with MVECs was analyzed by measuring the 
surface area (µm2) of the coincidence of the GFAP and CD31 signals in Volocity. The total sum surface 
area (µm2) of this astrocyte-blood vessel interaction was calculated per blood vessel and then averaged 
per animal. In the capillaries there was a significant increase in astrocyte-blood vessel contact area 
interactions and a trending increase in the thalamus. In the larger pre and post capillary vessels we also 
saw this trending increase (Fig. 14).  
 
Changes in Astrocyte Foot Process Contact Points with MVECs:  
Astrocytes are thought to give instructions to endothelial cells through their end feet 
contact points. Therefore we additionally, measured how many points of contact the astrocytes 
made with the endothelial cells. We observed a significant increase in contact points in 
capillaries from both the cortex and the thalamus in MPS IIIB compared to WT mice. While the 
Figure 14 Analysis of Astrocyte and Blood Vessel Interaction Changes in WT and MPS IIIB Mice.           
A) Capillary results of measuring the point of intersection of the CD31 and GFAP signals (µm2) show 
significant increase in astrocyte foot process contact with MVECs and a trending increase in the 
thalamus.  B) Pre and post capillary also show a trending increase astrocyte-blood vessel contact area. 
n = 5 
* p ≤ 0.05 
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increase for the larger vessels remained statistically not significant it did continue to show the 










Comparison of Pericyte Coverage of MVECs: 
 Pericyte coverage of MVECs were measured using the same method described for 
analyzing astrocyte foot process contact.  The pericyte-blood vessel interactions were measured 
from the coincidence of desmin and CD31 signals and the surface area was measured and 
analyzed in the same way described for the astrocyte-blood vessel interactions. No significant 
change was observed in the surface area in these desmin positive pericytes in any region or blood 
vessel grouping between WT and MPS IIIB animals (Fig. 16).  
 
Figure 15 Analysis of Astrocyte and Blood Vessel Interaction Changes in WT and MPS IIIB Mice.           
A) Measurements of the total points of contact where CD31 and GFAP signals intersect in the capillaries 
show significant increase in astrocyte foot process contact with MVECs in both the cortex and the 
thalamus.  B) Pre and post capillary also show a trending increase in astrocyte foot process contact with 
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Analysis of Pericyte Volume Between WT and MPS IIIB 
In addition to measuring the surface area of where desmin and CD31 intersected the 
volume of the total desmin signal was measured as well in order to determine if pericytes were 
swollen as suggested in literature31. No difference between WT and MPS IIIB pericyte volume 
was observed for either blood vessel group in both the cortex and the thalamus contrary to what 
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A B 
Figure 16 No Significant Changes in Surface Area Measurement of Pericyte Intersect Population No 
change in pericyte contact area between MPS IIIB and WT mice in the capillaries (A) or for the pre and 












Assessing Endothelial Cell Damage In MPS IIIB 
 Literature reports suggested endothelial cell damage in MPS IIIB31. Utilizing CD31 to 
visualize endothelial cells and their tight junctions we were able to visually confirm disruption to 
the endothelial cells suggesting tight junction damage.(Fig. 18). When quantified we observed a 
significant decrease in the percent of intact endothelial cells in capillaries from MPS IIIB mice 
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Figure 17 Analysis of Desmin Positive Pericyte Volume in WT and MPS IIIB Microvasculature No change in pericyte 
volume between MPS IIIB and WT mice in the capillaries (A) or the pre and post capillary vessels (B) of either the 














Figure 18 Comparison of Endothelial Cells in WT and MPS IIIB Mice Show Endothelial Cell 
Disruption A) A WT capillary with intact endothelial cells and undamaged tight junctions. B) An 
MPS IIIB capillary with disrupted endothelial cell damage equated to tight junction damage.  
A B 
Figure 19 Quantification of Endothelial Cell Disruption The percent of intact endothelial cells in 
MPS IIIB mice was measured in 10 randomly selected capillaries from the cortex of each animal 
in WT and MPS IIIB. A significant decrease in the amount of undamaged endothelial cells in MPS 






























































n = 5 




 The overall purpose of this project was to develop the tools and techniques 
needed to create a quantitative model of the BBB in normal adult mice that would then allow for 
the evaluation of the effects of development and disease on the BBB. To accomplish this goal, 
each component of the BBB was examined through immunohistochemistry, confocal 
microscopy, and 3D image analysis in order to quantify their relationship with the MVECs.  The 
initial stages were focused on optimizing an IHC protocol that would produce high quality 
staining of blood vessel endothelial cells in thick tissue sections costained with various other 
antibodies to identify the components of the BBB. A standard IHC experiment typically uses 
tissue sections 5-10 μm in thickness, however, in order to capture full cross section diameters of 
blood vessels, thicker tissues of 50 μm were utilized.  To maximize penetration of antibodies into 
these thicker tissue samples a staining protocol was developed using a floating tissue technique, 
rather than the more common method of staining tissues while mounted on a slide. This allowed 
the antibodies to have access to both sides of the tissue, increasing the depth of antibody 
penetration. Furthermore washing in this manner also was more effective in removing unbound 
antibody which can cause unwanted background signal.   
The significant finding of this project was support for the hypothesis that traditional 2D 
blood vessel analysis is indeed an inaccurate and invalid approach.  The development of a 3D 
protocol was a monumental task that took several different approaches before settling on the one 
used.  The requirements set in place this measurement protocol included that it must be efficient, 
accurate, reproducible, and would work with various blood vessel sizes and shapes.  Additional 
considerations included that the protocol require minimal computing power and also be 
automated but these were not considered requirements.  Early measurement protocol ideas 
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included the traditional 2D blood vessel diameter line measurement, which was quickly 
demonstrated too be inaccurate (Fig. 1 and Fig. 13). A second approach attempted was to 
measure the skeletal diameter of the blood vessels in Volocity which calculates the diameter 
based off the volume of a cylinder with the same volume and maximum length as the measured 
blood vessel. This method was determined to be inadequate as it relied too much on the 
maximum length of the blood vessel. The maximum length was calculated automatically by 
Volocity and was not always a straight line from one end of the vessel to the other, but rather 
would twist and turn throughout the volume depending on where the highest voxel intensity was 
localized.  The skeletal diameter approach led to the idea that an accurate diameter could be 
calculated from the volume of the blood vessel, using the formula for the volume of a cylinder, if 
the proper length of the blood vessel was measured. However, again this method was discarded 
due to the inability to reproduce accurate results which varied too much depending on the length, 
shape and volume of the blood vessels. The final attempted measurement protocol went back to 
the basic concepts of the 2D measurement approach, but rather than making a line measurement 
at one focal plane, line measurements across the apparent diameters were made in every slice of 
the image stacks and then averaged.  The advantage idea behind this approach was the idea that 
measuring through the entire image stack would account for all the changes that occur to the 
diameter size throughout the length of the blood vessel. However, the limitations to this approach 
included the length of it took to manually draw an accurate line in every image slice in stacks 
that averaged 150 slices. Secondly, the results from this approach were sensitive to the subjective 
decision of where and how the line measurement was drawn. For example, rarely do blood vessel 
cross sections appear as a perfect circle, more often they behave more as an ellipse with major 
and minor diameter axis, measuring the diameter along only one axis could potentially skew data 
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results inaccurately.  Based on these results it was then hypothesized that a simple line 
measurement whether it be in a single focal plane or averaged through an entire z-stack still 
would not provide the accuracy desired.  To solve these issues we instead measured the average 
cross-sectional area of blood vessel image stacks as a way to determine the average diameter. 
 The protocols and assays developed in this project, particularly for the blood vessel 
characterization, were not possible until the last few years.  Advances in both microscope and 
image analysis technologies have allowed for the hundreds of images and blood vessels required 
for this projects analysis to be analyzed in weeks rather than months or years, but room for 
advancement still exists. 
  Commercial 3D software programs such as, Volocity, offer a user-friendly interface to 
produce high quality 3D image visualization, as well as analysis tools. Unfortunately, the 
quantification power of these software can be limited by the scope of the software programming 
they are installed with. What Volocity and other recently developed 3D software systems lack is 
the customizability of the commonly used, open source, java language based ImageJ. The ability 
to adapt ImageJ processing functions to specific processing needs through custom built macros 
and plugins creates a much more powerful image processing platform. In order to make full use 
of the advantages of ImageJ however, a basic understanding of its programming language, Java, 
is necessary. Additionally, ImageJ was developed for 2D image processing and while 3D plugins 
exist and are beginning to advance, they lack the straightforward ease of use of the commercial 
products. 
 As a result of the various benefits and shortcomings of the available image processing 
software available a combination of the both Volocity and ImageJ were required in order to 
measure and classify the imaged blood vessels by their cross sectional area. By combining these 
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two image processing programs, a unique methodology for blood vessel classification was 
developed.  The major advantage of utilizing Volocity for the initial image processing is the 
ability to visually rotate the 3D structure around its axis until the vessel’s cross section is aligned 
with the xy plane of the image.  The reslice function in Volocity allows a new 3D blood vessel 
image in the desired orientation to be reconstructed in the orientation set by physically moving 
the original 3D blood vessel representation. The advantage of this method over the method 
offered in ImageJ is the ability to visualize in 3D how the vessel’s cross section is aligned with 
the xy image plane. In ImageJ users must know and input the x, y, and z angles that they wish 
the image to be aligned at without visual aid making this analysis more laborious.  
 As beneficial as Volocity is for 3D visualization and reorienting blood vessels there are 
limitations in evaluating the cross sectional area or diameters of resultant blood vessels in 3D. 
Therefore, images were exported into ImageJ so they could be analyzed using the custom written 
area measurement macro created for these image stacks.  The macro allowed the area within the 
vessel walls to be measured in every slice of an image stack and furthermore could be batch 
processed to automatically measure every blood vessel image stack in a designated folder.  
Requirements set to avoid incorrect object detection and thus false measurements included 
setting a minimum area requirement of 25 µm2. Additionally, in order to be detected as an object, 
not background, the blood vessel wall had to be completely enclosed, otherwise no measurement 
would occur.  Therefore, to improve the chances of a measurement occurring the open command 
was added to the measurement macro to close any small gaps in the vessel wall without altering 
the shape of the vessel cross section.  
 As a result of these measurement requirements approximately 60-70% of blood vessel 
images end up being eliminated from further analysis before they were categorized into their 
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different size classifications.  To overcome this severe drop off in eligible blood vessels 
approximately 150-200 images were acquired per animal in order to reach a minimum of 10 
eligible blood vessels per category.  Traditionally, the requirement of hundreds of large z-stack 
images would take weeks of around the clock imaging. However, advances in microscope 
technology, specifically with the Leica SP8 LSM, made it possible to image approximately 100 
z-stacks in 1-4 hours depending on acquisition settings. Therefore, by taking advantage of 
advancing image acquisition and processing technologies an accurate method of characterizing 
blood vessels by cross section area was created which overcomes the shortcomings of traditional 




Figure 20 Summary of Blood Vessel Classification Process 
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 Once blood vessels were measured and categorized with their size classifications blood 
vessels capillaries (< 10 µm) and pre and post capillary arterioles and venules (11-20 µm) were 
used in analysis to study changes in both astrocyte foot process and pericyte coverage of the 
MVECs. These two vessel groups have the most significant BBB function as well as make up the 
majority of vascular surface area within the brain. In Volocity, the resliced blood vessel images 
underwent a measurement protocol developed to measure the surface area of locations where a 
coincidence of voxels from CD31 (endothelial cells/blood vessel) and GFAP (astrocyte) or 
desmin (pericyte) signals both occur.  These areas of intersection represent where the astrocytes 
or pericytes have contact with the MVECs.  Qualitatively an increase of astrocyte coverage was 
observed in the MPS IIIB mouse brains compared to those of the WT mice.  This observation 
was quantitatively confirmed to be significant the capillaries of the cortex and to trend upward in 
all other measured vessels and regions.  Additionally, since astrocytes are believed to induce the 
barrier-like quality in the endothelial cells through instructive ques that occur through their end 
feet contact points, we looked at how many points of contact the astrocytes made with the 
endothelial cells. We observed a significant increase in the number of astrocyte contact points 
made with blood vessels in capillaries from both the cortex and the thalamus in MPS IIIB 
compared to WT mice as well as a continued trending increase in both regions of the larger 
blood vessels. These findings provide evidence to support reports that astrocytes have roles in 
both maintaining the BBB in health and repairing the BBB when damage occurs.  
To provide further support for our observations additional studies are required to 
determine if the observed increase in astrocyte-endothelial cell contact is indeed in reaction to 
BBB impairment. Mice used in this study were approximately 10 months old with disease 
manifestation well underway, in order adequately answer the questions regarding when the 
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astroglyosis and increased endothelial cell contact occur in relation to BBB permeability, a time 
course study of disease pathogenesis is required.  Utilizing the tools described here the time 
points of when BBB leakage is observed can be correlated with when increased astrocyte-
endothelial cell contact occurs, providing critical information into further understanding of this 
disease progression.  
 The effects of reported pericyte damage in MPS IIIB were analyzed by measuring the 
surface area of their coincidence with the blood vessel endothelial cells in the same manner as 
the astrocyte foot processes were. Interestingly no significant change was observed in these 
desmin positive pericytes in any region or blood vessel grouping between WT and disease.  
We find no convincing change therefore suggesting that swelling may not have a functional 
consequence. In fact when we measured to volume of these pericytes to analyze their swelling 
ourselves we saw no change.  Several interpretations of this data are possible including that, 
contrary to literature, pericytes have a relatively minor role in BBB integrity. Additional 
interpretations include that pericytes are reported to be a heterogeneous cell type and no one 
marker can adequately access them at any one time. Therefore, while desmin positive pericytes 
had no observable change in blood vessel contact there could be changes to pericytes expressing  
PDGFRB, ASMA, or NG2 that simply need to be studied as well.  A time course study, 
incorporating the analysis techniques developed here, as well as additional pericyte markers, is 
necessary in order to gain a better understanding of the pericyte population in this disease and as 
it relates to the BBB. 
According to the literature endothelial cells in MPS IIIB are swollen but this is only 
explored in ultrastructure analysis and not in the context of the entire vessel31. Additionally we 
wanted to try and understand the changes in astrocytes that we identified. So we looked at the 
52 
 
endothelial cells and their TJs using CD31 as discussed earlier. When we looked at them we also 
saw an apparent disruption of the endothelial cells along their tight junctions suggesting there is 
tight junction damage as well. When the percent of intact MVEC along the blood vessels length 
was measured we observed a significant decrease in the amount of undamaged MVECs along the 
TJs in capillaries in MPS IIIB mice suggesting that the changes we observed in BBB structural 
components is in response to BBB damage.  
From the observed results we created a visual model of the BBB in both WT and MPS 
IIIB (Fig. 21). In the WT model we have intact EC that equate to undamaged tight junctions, 
minimal astrocyte contact, and we saw desmin positive pericytes wrapping around the vessels. 
Then in MPS IIIB model we have the observed disrupted EC equaling damaged TJs, an increase 
of astrocyte contact area with the vessels for barrier support; as well as an increase in astrocyte 
contact points where they are instructing repair. Lastly no change in desmin positive pericyte 
contact area gave us no evidence of pericyte disruption contrary to what has been proposed in 
literature31.  
 The development of a detailed quantitative model of the BBB in both wild type mice and 
diseased states is a first of its kind. The novelty of 3D analysis provides precision to the study of 
vasculature interactions that has not been possible with 2D, and will reduce the margin of error 
that is typical in this type of analysis. Additionally, the information obtained from this 
characterization of the effect of disease on BBB integrity is invaluable in future drug treatment 
development plans including aiding in insight on disease pathology as well as developing 














Figure 21 Proposed Models of the BBB for WT and MPS IIIB A) WT BBB model with intact 
endothelial cells, minimal astrocyte foot process contact, and pericytes wrapped around the 
blood vessel. B) MPS IIIB BBB Model with disrupted endothelial cell, increased astrocyte contact 





1.  Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, 
regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1-13. 
doi:10.1016/j.nbd.2003.12.016. 
2.  Weiss N, Miller F, Cazaubon S, Couraud P-O. The blood-brain barrier in brain 
homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788(4):842-857. 
doi:10.1016/j.bbamem.2008.10.022. 
3.  Hawkins BT, Davis TP. The Blood-Brain Barrier / Neurovascular Unit in Health and 
Disease. 2005;57(2):173-185. doi:10.1124/pr.57.2.4.173. 
4.  Zlokovic B V. The blood-brain barrier in health and chronic neurodegenerative disorders. 
Neuron. 2008;57(2):178-201. doi:10.1016/j.neuron.2008.01.003. 
5.  Pardridge WM. Blood – brain barrier delivery. 2007;12(January):54-61. 
doi:10.1016/j.drudis.2006.10.013. 
6.  Jones AR, Shusta E V. Blood-Brain Barrier Transport of Therapeutics via Receptor-
Mediation. 2009;24(9):1759-1771. doi:10.1007/s11095-007-9379-0.Blood-Brain. 
7.  Xiao G, Gan L. Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic 
Biologics. 2013;2013. 
8.  Winkler EA, Bell RD, Zlokovic B V. Central nervous system pericytes in health and 
disease. Nat Neurosci. 2011;14(11):1398-1405. doi:10.1038/nn.2946. 
9.  Alberts B, Johnson A, Lewis J et al. Blood Vessels and Endothelial Cells. Molecular . 
New York: Garland Science; 2002. http://www.ncbi.nlm.nih.gov/books/NBK26848/. 
10.  Bazzoni G, Dejana E, Farmacologiche R, Negri M. Endothelial Cell-to-Cell Junctions : 
Molecular Organization and Role in Vascular Homeostasis. 2004:869-901. 
11.  Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug 
delivery. J Inherit Metab Dis. 2013;36(3):437-449. doi:10.1007/s10545-013-9608-0. 
12.  Luissint A-C, Artus C, Glacial F, Ganeshamoorthy K, Couraud P-O. Tight junctions at the 
blood brain barrier: physiological architecture and disease-associated dysregulation. 
Fluids Barriers CNS. 2012;9(1):23. doi:10.1186/2045-8118-9-23. 
13.  Wolburg H, Lippoldt A. Tight junctions of the blood – brain barrier : Development , 
composition and regulation. 2002;38:323-337. 
55 
 
14.  Engelhardt B. Development of the blood-brain barrier. 2003:119-129. 
doi:10.1007/s00441-003-0751-z. 
15.  Moy AJ, Wiersma MP, Choi B. Optical histology: a method to visualize microvasculature 
in thick tissue sections of mouse brain. PLoS One. 2013;8(1):e53753. 
doi:10.1371/journal.pone.0053753. 
16.  Sofroniew M V, Vinters H V. Astrocytes: biology and pathology. Acta Neuropathol. 
2010;119(1):7-35. doi:10.1007/s00401-009-0619-8. 
17.  Abbott NJ, Rönnbäck L, Hansson E. Astrocyte – endothelial interactions at the blood – 
brain barrier. 2006;7(January):41-53. doi:10.1038/nrn1824. 
18.  Abbott NJ. Astrocyte – endothelial interactions and blood – brain barrier permeability *. 
2002:629-638. 
19.  Willis CL, Nolan CC, Reith SN, et al. Focal Astrocyte Loss Is Followed by Microvascular 
Damage , With Subsequent Repair of the Blood-Brain Barrier in the Apparent Absence of 
Direct Astrocytic Contact. 2004;337(August 2003):325-337. doi:10.1002/glia.10333. 
20.  Zhou J, Kong H, Hua X, Xiao M, Ding J, Hu G. Altered blood-brain barrier integrity in 
adult aquaporin-4 knockout mice. Neuroreport. 2008;19(1):1-5. 
doi:10.1097/WNR.0b013e3282f2b4eb. 
21.  Rajkowska G, Hughes J, Stockmeier CA, Miguel-hidalgo JJ, Maciag D. Coverage of 
Blood Vessels by Astrocytic Endfeet. Biol Psychiatry. 2012;73(7):613-621. 
doi:10.1016/j.biopsych.2012.09.024. 
22.  Willis CL. Astrocytes. Milner R, ed. 2012;814:515-529. doi:10.1007/978-1-61779-452-0. 
23.  Avenue G. Endothelial/Pericyte Interactions. J Am Heart Assoc. 2005:512-523. 
doi:10.1161/01.RES.0000182903.16652.d7. 
24.  Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood–brain barrier. 
2010;(V):6-11. doi:10.1038/nature09522. 
25.  Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. 
Neuro Oncol. 2005;7(4):452-464. doi:10.1215/S1152851705000232. 
26.  Omidi Y, Barar J. Impacts of Blood-Brain Barrier in Drug Delivery and Targeting of 
Brain Tumors. 2012;2(1):5-22. doi:10.5681/bi.2012.002. 
27.  Sands MS. A Hitchhiker’s guide to the blood-brain barrier: in trans delivery of a 
therapeutic enzyme. Mol Ther. 2014;22(3):483-484. doi:10.1038/mt.2014.12. 
56 
 
28.  Zlokovic B V. Neurodegeneration and the neurovascular unit. Nat Med. 
2010;16(12):1370-1371. doi:10.1038/nm1210-1370. 
29.  Thal SC, Luh C, Schaible E-V, et al. Volatile anesthetics influence blood-brain barrier 
integrity by modulation of tight junction protein expression in traumatic brain injury. 
PLoS One. 2012;7(12):e50752. doi:10.1371/journal.pone.0050752. 
30.  Isasi E, Barbeito L, Olivera-Bravo S. Increased blood-brain barrier permeability and 
alterations in perivascular astrocytes and pericytes induced by intracisternal glutaric acid. 
Fluids Barriers CNS. 2014;11:15. doi:10.1186/2045-8118-11-15. 
31.  Garbuzova-Davis S, Louis MK, Haller EM, Derasari HM, Rawls AE, Sanberg PR. Blood-
brain barrier impairment in an animal model of MPS III B. PLoS One. 2011;6(3):e16601. 
doi:10.1371/journal.pone.0016601. 
32.  Weber B, Guo X, Kleijer WJ, Kamp JJP Van De, Poorthuis BJHM, Hopwood JJ. 
Sanfilippo type B syndrome ( mucopolysaccharidosis III B ): allelic heterogeneity 
corresponds to the wide spectrum of clinical phenotypes. 1999;(May 1998):34-44. 
33.  Li HH, Yu W, Rozengurt N, et al. Mouse model of Sanfilippo syndrome type B produced 
by targeted disruption of the gene encoding ␣ -N-acetylglucosaminidase. 1999;96(25). 
34.  Heldermon CD, Hennig AK, Ohlemiller KK, et al. Development of Sensory , Motor and 
Behavioral Deficits in the Murine Model of Sanfilippo Syndrome Type B. 2007;63104(8). 
doi:10.1371/journal.pone.0000772. 
35.  Zafeiriou DI, Batzios SP. Brain and spinal MR imaging findings in 
mucopolysaccharidoses: a review. AJNR Am J Neuroradiol. 2013;34(1):5-13. 
doi:10.3174/ajnr.A2832. 
36.  Xue Q, Liu Y, Qi H, et al. A novel brain neurovascular unit model with neurons, 
astrocytes and microvascular endothelial cells of rat. Int J Biol Sci. 2013;9(2):174-189. 
doi:10.7150/ijbs.5115. 
37.  Shawahna R, Decleves X, Scherrmann J-M. Hurdles with using in vitro models to predict 
human blood-brain barrier drug permeability: a special focus on transporters and 
metabolizing enzymes. Curr Drug Metab. 2013;14:120-136. 
http://www.ncbi.nlm.nih.gov/pubmed/23215812. 
38.  Goldstein M, Watkins S. Immunohistochemistry. Curr Protoc Mol Biol. 2008;Chapter 
14(January):Unit 14.6. doi:10.1002/0471142727.mb1406s81. 
39.  Lang E, Baier J, Kohler J. Epifluorescence , confocal and total internal reflection 




40.  Meding S, Walch A. Epi-Fluorescence Microscopy.; 2013. doi:10.1007/978-1-62703-056-
4. 
41.  Schermelleh L, Heintzmann R, Leonhardt H. A guide to super-resolution fluorescence 
microscopy. J Cell Biol. 2010;190(2):165-175. doi:10.1083/jcb.201002018. 
42.  Royal THE, Academy S, Sciences OF. Super-Resolved Fluorescence Microscopy. 
2014;50005. 
43.  Cox G. Biological confocal microscopy. Mater Today. 2002;5(3):34-41. 
doi:10.1016/S1369-7021(02)05329-4. 
44.  Ragazzi M, Piana S, Longo C, et al. Fluorescence confocal microscopy for pathologists. 
Mod Pathol. 2013;27(3):1-12. doi:10.1038/modpathol.2013.158. 
45.  Saubaméa B, Cochois-Guégan V, Cisternino S, Scherrmann J-M. Heterogeneity in the rat 
brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen 
and P-glycoprotein expression. J Cereb Blood Flow Metab. 2012;32(1):81-92. 
doi:10.1038/jcbfm.2011.109. 
46.  Paul D, Cowan AE, Ge S, Pachter JS. Novel 3D analysis of Claudin-5 reveals signi fi cant 
endothelial heterogeneity among CNS microvessels. Microvasc Res. 2013;86:1-10. 
doi:10.1016/j.mvr.2012.12.001. 
47.  Janáček J, Cvetko E, Kubínová L, Travnik L, Eržen I. A novel method for evaluation of 
capillarity in human skeletal muscles from confocal 3D images. Microvasc Res. 
2011;81(2):231-238. doi:10.1016/j.mvr.2010.11.012. 
48.  Macdonald JA, Murugesan N, Pachter JS. Endothelial Cell Heterogeneity of Blood-Brain 
Barrier Gene Expression Along the Cerebral Microvasculature. 2010;1474:1457-1474. 
doi:10.1002/jnr.22316. 
49.  Zudaire E, Gambardella L, Kurcz C, Vermeren S. A computational tool for quantitative 
analysis of vascular networks. PLoS One. 2011;6(11):e27385. 
doi:10.1371/journal.pone.0027385. 
50.  Biology D, Biology D, Regulation G, Sciences L, Dd D, Biology C. Evaluating 
performance in three-dimensional fluorescence. 2007;228(July):390-405. 
51.  Petzelbauer P, Halama T, Gro M. Endothelial Adherens Junctions. 2000:10-13.  
 
  
